Clinical trial results:
A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Summary

EudraCT number	2018-001436-22
Trial protocol	GB CZ DE ES IT
Global end of trial date	20 June 2022

Results information

Result version number	v1 (current)
This version publication date	16 July 2023
First version publication date	16 July 2023

Trial information

Trial identification

Sponsor protocol code	APL2-303

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03525600
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Apellis Pharmaceuticals, Inc
Sponsor organisation address	100 5th Avenue, Waltham, Massachusetts, United States, 02451
Public contact	Apellis Clinical Trial Information Line, Apellis Pharmaceuticals, Inc, +1 833-284-6361, clinicaltrials@apellis.com
Scientific contact	Apellis Clinical Trial Information Line, Apellis Pharmaceuticals, Inc, +1 833-284-6361, clinicaltrials@apellis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 June 2022
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 June 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of pegcetacoplan compared to sham injection in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) assessed by change in the total area of GA lesions in the study eye from baseline as measured by fundus autofluorescence (FAF) images.

Protection of trial subjects:

This research was carried out in accordance with the protocol, applicable regulations, the ethical principles set forth in the Declaration of Helsinki, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Harmonised Guideline for Good Clinical Practice E6 Revision 2. An external, independent data monitoring committee assessed the safety and tolerability data of the study periodically.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 60
Country: Number of subjects enrolled	Australia: 8
Country: Number of subjects enrolled	Brazil: 32
Country: Number of subjects enrolled	Canada: 7
Country: Number of subjects enrolled	Czechia: 14
Country: Number of subjects enrolled	France: 33
Country: Number of subjects enrolled	Germany: 18
Country: Number of subjects enrolled	Israel: 6
Country: Number of subjects enrolled	Italy: 3
Country: Number of subjects enrolled	New Zealand: 1
Country: Number of subjects enrolled	Poland: 15
Country: Number of subjects enrolled	Spain: 3
Country: Number of subjects enrolled	United Kingdom: 21
Country: Number of subjects enrolled	United States: 400
Worldwide total number of subjects	621
EEA total number of subjects	86

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	19
From 65 to 84 years	459
85 years and over	143

Subject disposition

Recruitment

Recruitment details:

This Phase III, randomized, double-masked, sham injection-controlled study was conducted in subjects with GA secondary to AMD at 122 investigational sites. A total of 621 subjects were randomized in this study.

Pre-assignment

Screening details:

This study consisted of a screening period (up to 30 days), a randomization visit on Day 1, and a treatment period (up to 24 months). Subjects were randomized in a 2:2:1:1 ratio on Day 1 to receive treatment with pegcetacoplan monthly, pegcetacoplan every other month (EOM), sham injection monthly or sham injection EOM, respectively.

Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Data analyst, Assessor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Pegcetacoplan Monthly

Arm description:

Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligram (mg)/0.1 milliliter (mL) once monthly for 24 months.

Arm type	Experimental
Investigational medicinal product name	Pegcetacoplan
Investigational medicinal product code	APL-2
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravitreal use

Dosage and administration details:

Subjects received IVT injections of pegcetacoplan 15 mg/0.1 mL once monthly by only qualified study staff. Administration of pegcetacoplan was only allowed if preinjection intraocular pressure (IOP) was <=21 millimeter of mercury (mm Hg).

Arm title	Pegcetacoplan EOM

Arm description:

Subjects received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.

Arm type	Experimental
Investigational medicinal product name	Pegcetacoplan
Investigational medicinal product code	APL-2
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravitreal use

Dosage and administration details:

Subjects received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM by only qualified study staff. Administration of pegcetacoplan was only allowed if preinjection IOP was <=21 mm Hg.

Arm title	Sham Monthly

Arm description:

Subjects received sham injections once monthly for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Sham EOM

Arm description:

Subjects received sham injections EOM for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 1	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Monthly
Started	206	208	102
Completed	147	161	78
Not completed	59	47	24
Physician decision	1	-	2
Consent withdrawn by subject	36	20	6
Adverse event, non-fatal	9	6	5
Death	7	6	4
Due to Coronavirus Disease-2019 (COVID-19) impact	4	10	3
Unspecified	-	1	-
Lost to follow-up	2	4	4

Number of subjects in period 1	Sham EOM
Started	105
Completed	83
Not completed	22
Physician decision	-
Consent withdrawn by subject	13
Adverse event, non-fatal	3
Death	3
Due to Coronavirus Disease-2019 (COVID-19) impact	3
Unspecified	-
Lost to follow-up	-

Baseline characteristics

Reporting groups	
Reporting group title	Pegcetacoplan Monthly
Reporting group description:	
Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligram (mg)/0.1 milliliter (mL) once monthly for 24 months.	
Reporting group title	Pegcetacoplan EOM
Reporting group description:	
Subjects received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.	
Reporting group title	Sham Monthly
Reporting group description:	
Subjects received sham injections once monthly for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	
Reporting group title	Sham EOM
Reporting group description:	
Subjects received sham injections EOM for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	

Reporting group values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Monthly
Number of subjects	206	208	102
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	78.8	79.2	78.9
standard deviation	± 6.91	± 7.06	± 7.34
Gender categorical Units: Subjects			
Female	121	126	65
Male	85	82	37
Race Units: Subjects			
White	192	192	99
Not reported	12	11	3
Black or African American	1	1	0
Asian	0	1	0
Multiple	0	1	0
Unknown	1	2	0
Ethnicity Units: Subjects			
Hispanic or Latino	32	37	13
Not Hispanic or Latino	163	155	87
Not Reported	10	12	2
Unknown	1	4	0
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye Units: Millimeter square (mm^2)			
arithmetic mean	8.3606	8.2076	8.3520

standard deviation	± 4.16892	± 3.91213	± 4.11553

Reporting group values	Sham EOM	Total	
Number of subjects	105	621	
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	78.1		
standard deviation	± 7.16	-	
Gender categorical Units: Subjects			
Female	67	379	
Male	38	242	
Race Units: Subjects			
White	101	584	
Not reported	3	29	
Black or African American	0	2	
Asian	0	1	
Multiple	0	1	
Unknown	1	4	
Ethnicity Units: Subjects			
Hispanic or Latino	16	98	
Not Hispanic or Latino	85	490	
Not Reported	4	28	
Unknown	0	5	
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye Units: Millimeter square (mm^2)			
arithmetic mean	8.1651		
standard deviation	± 4.33420	-	

Subject analysis sets

Subject analysis set title	Sham Pooled
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Sham Monthly: Subjects received sham injections once monthly for 24 months.
Sham EOM: Subjects received sham injections EOM for 24 months.
The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Subject analysis set title	Sham Pooled
Subject analysis set type	Modified intention-to-treat

Subject analysis set description:

Sham Monthly: Subjects received sham injections once monthly for 24 months.
Sham EOM: Subjects received sham injections EOM for 24 months.
The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Reporting group values	Sham Pooled	Sham Pooled	
Number of subjects	207	195	
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	78.5		
standard deviation	± 7.24	±	
Gender categorical Units: Subjects			
Female	132		
Male	75		
Race Units: Subjects			
White	200		
Not reported	6		
Black or African American	0		
Asian	0		
Multiple	0		
Unknown	1		
Ethnicity Units: Subjects			
Hispanic or Latino	29		
Not Hispanic or Latino	172		
Not Reported	6		
Unknown	0		
GA Lesion Size (fundus autofluorescence [FAF]) in the Study Eye Units: Millimeter square (mm^2)			
arithmetic mean	8.2572		
standard deviation	± 4.21864	±	

End points reporting groups

Reporting group title	Pegcetacoplan Monthly
Reporting group description:	
Subjects received intravitreal (IVT) injections of pegcetacoplan 15 milligram (mg)/0.1 milliliter (mL) once monthly for 24 months.	
Reporting group title	Pegcetacoplan EOM
Reporting group description:	
Subjects received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.	
Reporting group title	Sham Monthly
Reporting group description:	
Subjects received sham injections once monthly for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	
Reporting group title	Sham EOM
Reporting group description:	
Subjects received sham injections EOM for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	
Subject analysis set title	Sham Pooled
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
Sham Monthly: Subjects received sham injections once monthly for 24 months. Sham EOM: Subjects received sham injections EOM for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	
Subject analysis set title	Sham Pooled
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
Sham Monthly: Subjects received sham injections once monthly for 24 months. Sham EOM: Subjects received sham injections EOM for 24 months. The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.	

Primary: Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12

End point title	Least Squares (LS) Mean Change From Baseline in Total Area of GA Lesions in the Study Eye at Month 12[1]
End point description:	
The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a mixed effect model for repeated measure (MMRM) model. Baseline was defined as the last available, non-missing observation prior to first study drug administration. The modified intent-to-treat (mITT) analysis set consisted of all subjects assigned to treatment who received at least 1 injection of pegcetacoplan or sham and had baseline and at least 1 post-baseline value of GA lesion area in the study eye as assessed by FAF. Subjects with a baseline and at least 1 post-baseline value of the outcome at a scheduled visit by Month 12 were included in the analysis.	
End point type	Primary
End point timeframe:	
Baseline (screening) and Month 12	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	200	199	193	
Units: mm^2				
least squares mean (standard error)	1.7344 (± 0.07924)	1.7563 (± 0.07446)	1.9640 (± 0.09592)	

Statistical analyses

Statistical analysis title	Treatment difference in total area of GA lesions
Statistical analysis description:	
Model included treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) + analysis visit + presence of choroidal neovascularization (CNV) in the fellow eye (yes or no) + analysis visit × treatment + baseline GA lesion area × analysis visit.	
Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	393
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0615
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.2296
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4703
upper limit	0.0111

Statistical analysis title	Treatment difference in total area of GA lesions
Statistical analysis description:	
Model included treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) + analysis visit + presence of CNV in the fellow eye (yes or no) + analysis visit × treatment + baseline GA lesion area × analysis visit.	
Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	392
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0854
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.2077
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4444
upper limit	0.029

Secondary: LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24

End point title	LS Mean Change From Baseline in the Total Area of GA Lesions in the Study Eye at Month 24[2]

End point description:

The GA lesion area was measured by a quantified central reading center based on FAF images. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration. The mITT analysis set consisted of all subjects assigned to treatment who received at least 1 injection of pegcetacoplan or sham and had baseline and at least 1 post-baseline value of GA lesion area in the study eye as assessed by FAF. Subjects with a baseline and at least 1 post-baseline value of the outcome at a scheduled visit by Month 24 were included in the analysis.

End point type	Secondary

End point timeframe:

Baseline (screening) and Month 24

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	200	200	194	
Units: mm^2				
least squares mean (standard error)	3.2275 (± 0.12457)	3.3395 (± 0.13034)	3.9726 (± 0.16820)	

Statistical analyses

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Model included treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) + analysis visit + baseline presence of CNV in the fellow eye (yes or no) + analysis visit × treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) × analysis visit.

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	394
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0004
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.7451
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1539
upper limit	-0.3362

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Model included treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) + analysis visit + baseline presence of CNV in the fellow eye (yes or no) + analysis visit × treatment + baseline GA lesion area (<7.5 mm^2 or ≥7.5 mm^2) × analysis visit.

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	394
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.6331
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.0508
upper limit	-0.2153

Secondary: Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24

End point title	Mean Change in Total Area of GA Lesions in the Study Eye Through Month 24[3]

End point description:

The mean change in GA lesion area through Month 24 was measured by assuming a piecewise linear trend in time with knots by FAF images at Months 6, 12, and 18 and was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration. The mITT analysis set consisted of all subjects assigned to treatment who received at least 1 injection of pegcetacoplan or sham and had baseline and at least 1 post-baseline value of GA lesion area in the study eye as assessed by FAF.

End point type	Secondary

End point timeframe:

From Baseline (screening) through Month 24

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	201	201	195	
Units: mm^2				
least squares mean (standard error)				
From Baseline to Month 6	0.9075 (± 0.04755)	0.8829 (± 0.04660)	0.9622 (± 0.04983)	
From Month 6 to Month 12	0.8409 (± 0.05128)	0.8473 (± 0.05086)	1.0132 (± 0.05998)	

From Month 12 to Month 18	0.9033 (± 0.04917)	0.8803 (± 0.05105)	1.0483 (± 0.05574)	
From Month 18 to Month 24	0.6262 (± 0.06809)	0.6946 (± 0.05256)	0.9794 (± 0.05469)	
From Baseline to Month 24	3.2780 (± 0.12525)	3.3051 (± 0.12871)	4.0031 (± 0.16880)	

Statistical analyses

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Baseline to Month 6: Model included Treatment + Baseline GA lesion area (<7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[4]
P-value	= 0.4282
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.0547
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.1899
upper limit	0.0806

Notes:

[4] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Baseline to Month 6: Model included Treatment + Baseline GA lesion area (<7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[5]
P-value	= 0.2457
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.0793

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2131
upper limit	0.0546

Notes:

[5] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 6 to Month 12: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[6]
P-value	= 0.0292
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.1722
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.327
upper limit	-0.0174

Notes:

[6] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 6 to Month 12: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[7]
P-value	= 0.0352
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.1659

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3202
upper limit	-0.0115

Notes:

[7] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 12 to Month 18: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[8]
P-value	= 0.0514
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.145
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.2909
upper limit	0.0009

Notes:

[8] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 12 to Month 18: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[9]
P-value	= 0.0265
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.168

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.3164
upper limit	-0.0196

Notes:

[9] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 18 to Month 24: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[10]
P-value	< 0.0001
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.3532
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.5245
upper limit	-0.1819

Notes:

[10] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Month 18 to Month 24: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[11]
P-value	= 0.0002
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.2848

Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.4336
upper limit	-0.1361

Notes:

[11] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Baseline to Month 24: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan Monthly v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[12]
P-value	= 0.0006
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.7251
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1373
upper limit	-0.3129

Notes:

[12] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Statistical analysis title	Treatment difference in total area of GA lesions

Statistical analysis description:

Estimates for Baseline to Month 24: Model included Treatment + Baseline GA lesion area (< 7.5 mm^2 or >= 7.5 mm^2) + Time (continuous) + Time Spline at Month 6 (continuous) + Time Spline at Month 12 (continuous) + Time Spline at Month 18 (continuous) + Presence of CNV in the fellow eye (Yes or No) + Time (continuous) x Treatment + Time Spline at Month 6 (continuous) x Treatment + Time Spline at Month 12 (continuous) x Treatment + Time Spline at Month 18 (continuous) x Treatment +

Comparison groups	Pegcetacoplan EOM v Sham Pooled
Number of subjects included in analysis	396
Analysis specification	Pre-specified
Analysis type	superiority[13]
P-value	= 0.001
Method	MMRM model
Parameter estimate	LS Mean Difference
Point estimate	-0.698

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.1142
upper limit	-0.2817

Notes:

[13] - Baseline GA lesion area x Time (continuous) + Baseline GA lesion area x Time Spline at Month 6 (continuous) + Baseline GA lesion area x Time Spline at Month 12 (continuous) + Baseline GA lesion area x Time Spline at Month 18 (continuous). A heterogeneous autoregressive covariance matrix was used to model within-subject errors.

Secondary: LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24

End point title	LS Mean Change From Baseline in Monocular Maximum Reading Speed of the Study Eye at Month 24[14]

End point description:

The maximum reading speed of the study eye was calculated per Minnesota Low-Vision Reading Test (MNREAD) or Radner Reading Charts user manuals, with no adjustment for reading inaccuracy. An additional step to cap resulting reading speed values at a maximum of 300 words per minute (wpm) was implemented. Maximum reading speed was calculated as the mean of the 3 highest non-zero reading speeds (or 2, or 1 value, as available), except when all wpm were calculated as 0 then the maximum reading speed was calculated as 0. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration. The mITT analysis set. Subjects with a baseline and at least 1 post-baseline value of the outcome at a scheduled visit by Month 24 were included in the analysis.

End point type	Secondary

End point timeframe:

Baseline (screening) and Month 24

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	179	163	164	
Units: wpm				
least squares mean (standard error)	-22.897 (± 4.1171)	-25.532 (± 2.7676)	-22.355 (± 2.9341)	

Statistical analyses

No statistical analyses for this end point

Secondary: LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24

End point title	LS Mean Change From Baseline in Mean Functional Reading Independence (FRI) Index Score at Month 24[15]

End point description:

The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD subjects. It had 1 total index score. For each FRI Index reading activity performed in the past 7 days, subjects were asked about the extent to which they required assistance beyond eyeglasses/contact lenses, including the use of low-vision aids, adjustments in the activity, or help from another subject. Mean FRI Index scores ranged from 1 (unable to do independently) to 4

(totally independent), with higher scores indicating higher functional reading independence. A negative change from baseline indicated a decrease in the FRI, disease worsening. LS mean was calculated using a MMRM model. Baseline was defined as the last available, non-missing observation prior to first study drug administration. The mITT analysis set. Subjects with a baseline and at least 1 post-baseline value of the outcome at a scheduled visit by Month 24 were included in the analysis.

End point type	Secondary

End point timeframe:

Baseline (screening) and Month 24

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	186	183	178	
Units: score on a scale				
least squares mean (standard error)	-0.408 (± 0.0570)	-0.371 (± 0.0562)	-0.360 (± 0.0601)	

Statistical analyses

No statistical analyses for this end point

Secondary: LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24

End point title	LS Mean Change From Baseline in Normal-Luminance Best-Corrected Visual Acuity (NL-BCVA) Score of the Study Eye at Month 24[16]

End point description:

The NL-BCVA was assessed by early treatment diabetic retinopathy study (ETDRS) chart prior to dilating the eyes at a starting distance of 4 meters and ranged from 0 (least score) to 100 (best score). If the 4-meter score was >19 letters read correctly, the visual acuity score was the sum of total letters correctly read at 4 meters plus the addition of 30. If the 4-meter score was ≤19 letters read correctly, the visual acuity score was the sum of total letters read correctly at 4 meters and total letters read correctly at the 1-meter distance. If no letters were read correctly at either the 4-meter distance or the 1-meter distance, the visual acuity score was 0. A positive change in the value indicated improvement in visual acuity. LS mean was calculated using a MMRM model. The mITT analysis set. Subjects with a baseline and at least 1 post-baseline value of the outcome at a scheduled visit by Month 24 were included in the analysis.

End point type	Secondary

End point timeframe:

Baseline (screening) and Month 24

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Subjects who received sham injections were pooled in this endpoint analysis.

End point values	Pegcetacoplan Monthly	Pegcetacoplan EOM	Sham Pooled	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	201	201	195	
Units: ETDRS letter score				
least squares mean (standard error)	-8.126 (± 1.0182)	-8.947 (± 1.0322)	-6.217 (± 1.0167)	

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

Treatment-emergent adverse events (TEAEs) were reported from first study drug administration (Day 1) up to 30 and 60 days after the last study drug administration for monthly and EOM treatment groups respectively, a maximum of 24 months

Adverse event reporting additional description:

The Safety analysis set consisted of all randomized subjects who received at least 1 injection of pegcetacoplan or sham. Ocular TEAEs are presented separately for the study and fellow eyes, and non-ocular (systemic) TEAEs are also presented.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	23.1

Reporting groups

Reporting group title	Pegcetacoplan Monthly: Ocular Study Eye

Reporting group description:

Ocular TEAEs were summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL once monthly for 24 months.

Reporting group title	Pegcetacoplan EOM: Ocular Study Eye

Reporting group description:

Ocular TEAEs were summarized for the study eye for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.

Reporting group title	Sham Pooled: Ocular Study Eye

Reporting group description:

Ocular TEAEs were summarized for the study eye for all subjects who were randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 24 months.
Sham EOM: Subjects received sham injections EOM for 24 months.
The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Reporting group title	Pegcetacoplan Monthly: Ocular Fellow Eye

Reporting group description:

Ocular TEAEs were summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL once monthly for 24 months.

Reporting group title	Pegcetacoplan EOM: Ocular Fellow Eye

Reporting group description:

Ocular TEAEs were summarized for the fellow eye for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.

Reporting group title	Sham Pooled: Ocular Fellow Eye

Reporting group description:

Ocular TEAEs were summarized for the fellow eye for all subjects who were randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 24 months.
Sham EOM: Subjects received sham injections EOM for 24 months.
The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Reporting group title	Pegcetacoplan Monthly: Non-ocular

Reporting group description:

Non-ocular (systemic) TEAEs were summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL once monthly for 24 months.

Reporting group title	Pegcetacoplan EOM: Non-ocular

Reporting group description:

Non-ocular (systemic) TEAEs were summarized for all subjects who received IVT injections of pegcetacoplan 15 mg/0.1 mL EOM for 24 months.

Reporting group title	Sham Pooled: Non-ocular

Reporting group description:

Non-ocular (systemic) TEAEs were summarized for all subjects who were randomized to sham monthly and sham EOM treatment groups.
Sham Monthly: Subjects received sham injections once monthly for 24 months.
Sham EOM: Subjects received sham injections EOM for 24 months.
The procedure for sham injection was the same as that used for IVT injection until the actual injection but no actual injection occurred.

Serious adverse events	Pegcetacoplan Monthly: Ocular Study Eye	Pegcetacoplan EOM: Ocular Study Eye	Sham Pooled: Ocular Study Eye
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 206 (1.94%)	2 / 208 (0.96%)	2 / 206 (0.97%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hairy cell leukaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer recurrent			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip neoplasm			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage II			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage III			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the oral cavity			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial spreading melanoma stage III			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acoustic neuroma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung carcinoma cell type unspecified stage I			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroid melanoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accelerated hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ill-defined disorder			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic prolapse			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Breath sounds abnormal			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaesthetic complication			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cervical vertebral fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Cataract			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry age-related macular degeneration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iridocyclitis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular hole			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal tear			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uveitis			
subjects affected / exposed	0 / 206 (0.00%)	2 / 208 (0.96%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitritis			

subjects affected / exposed	2 / 206 (0.97%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal prolapse			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Precancerous skin lesion			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin exfoliation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathogen resistance			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Electrolyte imbalance			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid retention			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Pegcetacoplan Monthly: Ocular Fellow Eye	Pegcetacoplan EOM: Ocular Fellow Eye	Sham Pooled: Ocular Fellow Eye
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hairy cell leukaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer recurrent			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip neoplasm			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage II			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage III			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Plasma cell myeloma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superficial spreading melanoma stage III			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acoustic neuroma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung carcinoma cell type unspecified stage I			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroid melanoma			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accelerated hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ill-defined disorder			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic prolapse			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Major depression			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Breath sounds abnormal			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anaesthetic complication			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure chronic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry age-related macular degeneration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iridocyclitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular hole			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal tear			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Uveitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal prolapse			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Precancerous skin lesion			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin exfoliation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Kidney infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathogen resistance			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Electrolyte imbalance			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid retention			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Pegcetacoplan Monthly: Non-ocular	Pegcetacoplan EOM: Non-ocular	Sham Pooled: Non-ocular
Total subjects affected by serious adverse events			
subjects affected / exposed	61 / 206 (29.61%)	47 / 208 (22.60%)	53 / 206 (25.73%)
number of deaths (all causes)	8	6	8
number of deaths resulting from adverse events	8	6	8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bladder cancer			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial cancer			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hairy cell leukaemia			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer recurrent			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip neoplasm			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage II			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung adenocarcinoma stage III			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Plasma cell myeloma			

subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Prostate cancer			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Superficial spreading melanoma stage III			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acoustic neuroma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of colon			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder transitional cell carcinoma			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colon cancer			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung carcinoma cell type unspecified stage I			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasm malignant			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Choroid melanoma			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 206 (0.97%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accelerated hypertension			

subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Ill-defined disorder			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Influenza like illness			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Pelvic prolapse			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	2 / 206 (0.97%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	1 / 206 (0.49%)	2 / 208 (0.96%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic respiratory failure			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pulmonary hypertension			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Psychiatric disorders			

Major depression			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disorientation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Breath sounds abnormal			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	3 / 206 (1.46%)	3 / 208 (1.44%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	2 / 206 (0.97%)	1 / 208 (0.48%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Anaesthetic complication			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical vertebral fracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot fracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			

subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radius fracture			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve stenosis			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Atrial fibrillation			
subjects affected / exposed	3 / 206 (1.46%)	2 / 208 (0.96%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block complete			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 206 (0.49%)	2 / 208 (0.96%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	1 / 1
Cardiac failure chronic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular failure			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	2 / 206 (0.97%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	3 / 206 (1.46%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	5 / 206 (2.43%)	2 / 208 (0.96%)	3 / 206 (1.46%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Syncope			
subjects affected / exposed	4 / 206 (1.94%)	2 / 208 (0.96%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	2 / 206 (0.97%)	2 / 208 (0.96%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebellar infarction			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral infarction			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolic stroke			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhagic stroke			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial aneurysm			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Carotid artery stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic encephalopathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry age-related macular degeneration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iridocyclitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Macular hole			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic ischaemic neuropathy			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal tear			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Uveitis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Visual acuity reduced			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitritis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	2 / 206 (0.97%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal prolapse			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	2 / 206 (0.97%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Drug eruption			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Precancerous skin lesion			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			

subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin exfoliation			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 206 (0.00%)	2 / 208 (0.96%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Inappropriate antidiuretic hormone secretion			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			

subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dupuytren's contracture			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint swelling			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	2 / 206 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spondylolisthesis			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	2 / 206 (0.97%)	7 / 208 (3.37%)	3 / 206 (1.46%)
occurrences causally related to treatment / all	0 / 2	0 / 7	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			

subjects affected / exposed	2 / 206 (0.97%)	3 / 208 (1.44%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 1
Sepsis			
subjects affected / exposed	0 / 206 (0.00%)	4 / 208 (1.92%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 206 (0.97%)	2 / 208 (0.96%)	3 / 206 (1.46%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	2 / 206 (0.97%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 206 (0.00%)	2 / 208 (0.96%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	1 / 206 (0.49%)	1 / 208 (0.48%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cellulitis			

subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	0 / 206 (0.00%)	1 / 208 (0.48%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Kidney infection			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pathogen resistance			
subjects affected / exposed	1 / 206 (0.49%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Electrolyte imbalance			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid retention			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	1 / 206 (0.49%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Pegcetacoplan Monthly: Ocular Study Eye	Pegcetacoplan EOM: Ocular Study Eye	Sham Pooled: Ocular Study Eye
Total subjects affected by non-serious adverse events			
subjects affected / exposed	113 / 206 (54.85%)	82 / 208 (39.42%)	61 / 206 (29.61%)
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Conjunctival haemorrhage			
subjects affected / exposed	12 / 206 (5.83%)	15 / 208 (7.21%)	5 / 206 (2.43%)
occurrences (all)	16	21	6
Eye irritation			
subjects affected / exposed	10 / 206 (4.85%)	4 / 208 (1.92%)	11 / 206 (5.34%)
occurrences (all)	13	5	12
Eye pain			
subjects affected / exposed	13 / 206 (6.31%)	8 / 208 (3.85%)	13 / 206 (6.31%)
occurrences (all)	18	9	15
Neovascular age-related macular degeneration			
subjects affected / exposed	21 / 206 (10.19%)	10 / 208 (4.81%)	5 / 206 (2.43%)
occurrences (all)	22	10	6
Retinal haemorrhage			
subjects affected / exposed	9 / 206 (4.37%)	15 / 208 (7.21%)	8 / 206 (3.88%)
occurrences (all)	9	15	9
Visual acuity reduced			
subjects affected / exposed	16 / 206 (7.77%)	6 / 208 (2.88%)	10 / 206 (4.85%)
occurrences (all)	16	8	11
Vitreous detachment			
subjects affected / exposed	8 / 206 (3.88%)	14 / 208 (6.73%)	6 / 206 (2.91%)
occurrences (all)	8	14	6
Vitreous floaters			
subjects affected / exposed	24 / 206 (11.65%)	10 / 208 (4.81%)	3 / 206 (1.46%)
occurrences (all)	29	12	3
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Back pain			

subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Pegcetacoplan Monthly: Ocular Fellow Eye	Pegcetacoplan EOM: Ocular Fellow Eye	Sham Pooled: Ocular Fellow Eye
Total subjects affected by non-serious adverse events			
subjects affected / exposed	35 / 206 (16.99%)	34 / 208 (16.35%)	29 / 206 (14.08%)
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Conjunctival haemorrhage			
subjects affected / exposed	1 / 206 (0.49%)	4 / 208 (1.92%)	1 / 206 (0.49%)
occurrences (all)	1	4	1
Eye irritation			
subjects affected / exposed	2 / 206 (0.97%)	2 / 208 (0.96%)	1 / 206 (0.49%)
occurrences (all)	2	2	1
Eye pain			
subjects affected / exposed	2 / 206 (0.97%)	2 / 208 (0.96%)	1 / 206 (0.49%)
occurrences (all)	2	3	1
Neovascular age-related macular degeneration			
subjects affected / exposed	7 / 206 (3.40%)	11 / 208 (5.29%)	8 / 206 (3.88%)
occurrences (all)	8	11	8
Retinal haemorrhage			

subjects affected / exposed	2 / 206 (0.97%)	4 / 208 (1.92%)	7 / 206 (3.40%)
occurrences (all)	3	5	8
Visual acuity reduced			
subjects affected / exposed	10 / 206 (4.85%)	6 / 208 (2.88%)	4 / 206 (1.94%)
occurrences (all)	11	7	4
Vitreous detachment			
subjects affected / exposed	8 / 206 (3.88%)	4 / 208 (1.92%)	3 / 206 (1.46%)
occurrences (all)	8	4	3
Vitreous floaters			
subjects affected / exposed	3 / 206 (1.46%)	1 / 208 (0.48%)	4 / 206 (1.94%)
occurrences (all)	3	1	4
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
COVID-19			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Pegcetacoplan Monthly: Non-ocular	Pegcetacoplan EOM: Non-ocular	Sham Pooled: Non-ocular
Total subjects affected by non-serious adverse events			
subjects affected / exposed	90 / 206 (43.69%)	70 / 208 (33.65%)	101 / 206 (49.03%)

Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	10 / 206 (4.85%)	15 / 208 (7.21%)	21 / 206 (10.19%)
occurrences (all)	16	20	30
Vascular disorders			
Hypertension			
subjects affected / exposed	17 / 206 (8.25%)	16 / 208 (7.69%)	15 / 206 (7.28%)
occurrences (all)	18	16	15
Eye disorders			
Conjunctival haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Eye irritation			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Neovascular age-related macular degeneration			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Retinal haemorrhage			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Vitreous detachment			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Vitreous floaters			
subjects affected / exposed	0 / 206 (0.00%)	0 / 208 (0.00%)	0 / 206 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Diarrhoea			

subjects affected / exposed	6 / 206 (2.91%)	8 / 208 (3.85%)	12 / 206 (5.83%)
occurrences (all)	6	8	12
Nausea			
subjects affected / exposed	11 / 206 (5.34%)	1 / 208 (0.48%)	5 / 206 (2.43%)
occurrences (all)	12	1	5
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	10 / 206 (4.85%)	6 / 208 (2.88%)	14 / 206 (6.80%)
occurrences (all)	16	8	16
Back pain			
subjects affected / exposed	12 / 206 (5.83%)	4 / 208 (1.92%)	6 / 206 (2.91%)
occurrences (all)	13	5	7
Infections and infestations			
COVID-19			
subjects affected / exposed	8 / 206 (3.88%)	7 / 208 (3.37%)	11 / 206 (5.34%)
occurrences (all)	8	7	11
Urinary tract infection			
subjects affected / exposed	17 / 206 (8.25%)	13 / 208 (6.25%)	21 / 206 (10.19%)
occurrences (all)	30	15	36

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
31 May 2018	Study objectives were expanded to describe the endpoints that would be utilized to meet them. Added that exploratory objectives utilizing digital applications would be conducted in select sites/countries only as these applications would be utilized according to local regulation. Clarified that to participate in the study, subjects must be diagnosed with GA of the macula secondary to AMD in the study eye. Added that if both eyes had the same visual acuity score, the right eye would be selected as the study eye. “Endothelial cell count” was removed as an assessment that was provided to the reading center for objective assessment of subject eligibility. The optical coherence tomography angiography (OCT-A) (selected sites only) was added as an assessment that was provided to the reading center for objective assessment of subject eligibility. The OCT-A was added as a monitoring assessment for select sites to confirm the diagnosis of new active CNV. “Country” was removed as a stratification factor. Blood volume for genetic biorepository was updated. Amended to clarify that all serious adverse events would be reported to the safety monitor by the investigator via fax or email within 1 working calendar day of becoming aware of the event, whether or not the serious events are deemed drug related. Clarified that the study staff performing visual acuity should be masked to the treatment assignment only; the protocol had previously stated that staff should also be masked to the study eye.
08 August 2018	Exclusion criteria modified for clarity and to exclude subjects with history of IVT injection in either eye. An exclusion criterion was added "Prior participation in another interventional clinical study for GA in either eye including investigational oral medication and placebo". Clarified that the following endpoint will not be limited to select sites only: Change from Baseline at each planned assessment in the total area of GA lesion(s) in the study eye (in mm^2) as assessed by FAF. Noted that the National Eye Institute 25-Item Visual Function Questionnaire distance activity and near activity subscale score endpoints would be conducted in select countries as these subscales were not available in all languages. Masking language was modified to indicate that the Principal Investigator was required to remain masked to subjects’ treatment assignments, while the treating physician and any associated support staff involved in study drug administration would be unmasked. Guidance on the treatment of new exudation related to active CNV in the study eye and/or fellow eye was modified to clarify that the reading center would provide a report to indicate whether or not there was evidence of active, exudative AMD, and the investigator would then determine if anti-vascular endothelial growth factor (VEGF) treatment should be initiated. Clarified that either ranibizumab or aflibercept should be selected as anti-VEGF therapy, unmasked investigator should administer anti-VEGF treatment if the treatment was administered on the same day as APL-2. Any treatments of therapies administered to the fellow eye within 5 years of screening should be recorded as a concomitant medication. Clarified that: In the event that a subject was suspected to have new active CNV in the study eye and/or the fellow eye, spectral domain optical coherence tomography and fluorescein angiography using the protocol specified procedures should be performed and sent to reading center to confirm diagnosis.

14 February 2019	The Pharmacokinetic and complement profile assessments were removed from this study. Updated to include the following statement: In recent studies conducted with APL-2 IVT from a single manufacturer, events of transient moderate and severe intraocular inflammation have been observed. The treatment administration section was revised to allow study treatment administration to occur on a day separate from the assessment visit. The procedure for sham injection was further described. Throughout the study procedures section it had also been noted that endothelial cell count assessment was for "select sites only." This had been previously noted in the schedule of events but not consistently in the body of the protocol. In addition, FAF and near-infrared reflectance were no longer "study eye only". The following assessments were removed as they would no longer be conducted at the screening visit: Low-luminance BCVA; Endothelial cell count; and OCT-A. The following assessments were added at Day 1: Endothelial cell count; and OCT-A (select sites).
27 April 2020	An appendix was added to include information related to COVID-19–related changes to the study. Rescreening procedure: If a subject was deemed a screen failure for not being able to meet the original screening window (Day −28 to Day −1 [±2 days]) due to COVID-19 related restrictions, a rescreening visit was allowed. Extended study drug administration windows. Temporary changes to masking rules: Every masked individual who performed study drug administration and/or post-injection assessment (all unmasked assessment) as a temporary measure, was permanently considered an unmasked individual and was not able to perform masked assessments once these exemptions were lifted.
12 August 2020	Added the descriptor "maximum" when referencing reading speed. Removed the 6-month follow-up period and updated the study length from 30 months to 24 months and made it a 30- or 60-day follow-up period based on treatment group because that length of time is deemed sufficient to evaluate the safety of pegcetacoplan based on its half-life in the vitreous. Additionally, there was an option for subjects to enroll in a separate extension study (APL2-GA-305 study) during which longer-term safety and efficacy will be collected.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
24 September 2018	This study was temporarily paused in September 2018 after 2 subjects had events of intraocular inflammation in the study eye. A thorough investigation concluded that these events were caused by an impurity in the polyethylene glycol diol starting material that had been introduced during the manufacturing process. The manufacturing process was modified to eliminate the impurity, and additional process controls were implemented to ensure its level remained below the limit of quantitation. Pegcetacoplan was then introduced in a small safety study (Study APL2-103) to evaluate the safety of new lots of drug product in subjects with low vision. Study APL2-303 restarted in March 2019.	04 March 2019

Notes:

Limitations and caveats

None reported